X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/teva-viatris-win-new-chance-challenge-jj-schizophrenia-drug-patent-2024-04-01/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210397
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211995
https://www.pharmatimes.com/news/byannli_authorised_in_britain_for_schizophrenia_treatment_1387028
http://www.pharmafile.com/news/596805/european-commission-approves-byannli-management-schizophrenia-adults
https://www.prnewswire.com/news-releases/janssen-announces-us-fda-approval-of-invega-hafyera-6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia-301366768.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211149
https://www.businesswire.com/news/home/20201204005162/en/Janssen-Submits-Marketing-Authorisation-Extension-to-the-European-Medicines-Agency-to-Register-Paliperidone-Palmitate-6-Monthly-PP6M-for-Treatment-of-Schizophrenia-in-Adults
https://www.prnewswire.com/news-releases/janssen-submits-paliperidone-palmitate-6-month-pp6m-supplemental-new-drug-application-to-us-fda-for-treatment-of-schizophrenia-in-adults-301164580.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-invega-trinza-207946-paliperidone-palmitate-extended-release-injectable-suspension-546-mg175-ml-1597495208.pdf
https://www.ema.europa.eu/en/documents/assessment-report/paliperidone-janssen-cilag-international-epar-public-assessment-report_en.pdf
https://www.prnewswire.com/news-releases/janssen-signs-results-based-contract-with-oklahoma-health-care-authority-ohca-for-its-long-acting-injectable-schizophrenia-medicines-300765003.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-invega-sustennapaliperidone-palmitate-extended-release-injectable-suspension-1512710971.pdf
http://www.businesswire.com/news/home/20171026005713/en/Alkermes-Initiate-New-Clinical-Study-Evaluating-ARISTADA%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
http://www.pharmaasia.com/2016/04/janssen-receives-chmp-positive-opinion-trevicta/
http://www.janssenpharmaceuticalsinc.com/assets/Invega%20Trinza%20Approval%20Press%20Release%20Clean%205%2018%2015%20-%20FINAL.pdf
http://www.fiercepharma.com/story/jj-promises-new-uses-old-meds-keep-pharma-sales-flying-high/2015-05-20
http://connect.dcat.org/blogs/pharma-news/2015/05/15/jj-receives-fda-complete-response-letter-for#.VVbj57mqqko
http://blogs.wsj.com/pharmalot/2015/01/22/coverage-for-gileads-sovaldi-is-delayed-in-england-over-cost/
http://www.prnewswire.com/news-releases/fda-grants-priority-review-for-three-month-paliperidone-palmitate-for-the-treatment-of-schizophrenia-300022224.html
Market Place
Share 
